Michael Herold

Obinutuzumab for the First-Line Treatment of Follicular Lymphoma

Robert Marcus, Andrew Davies, Kiyoshi Ando et al. · New England Journal of Medicine · 2017 · 788 citations · Full text

Medicine, Immunology, Oncology +14

Rituximab Added to First-Line Mitoxantrone, Chlorambucil, and Prednisolone Chemotherapy Followed by Interferon Maintenance Prolongs Survival in Patients With Advanced Follicular Lymphoma: An East German Study Group Hematology and Oncology Study

Michael Herold, Antje Haas, Stefanie Srock et al. · Journal of Clinical Oncology · 2007 · 504 citations

Medicine, Hematology, Pharmacotherapy +17

Immunochemotherapy With Obinutuzumab or Rituximab for Previously Untreated Follicular Lymphoma in the GALLIUM Study: Influence of Chemotherapy on Efficacy and Safety

Wolfgang Hiddemann, Anna Maria Barbui, Miguel Canales et al. · Journal of Clinical Oncology · 2018 · 234 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +16

Treatment of Bendamustine and Prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with Melphalan and Prednisone—a randomized phase III study of the East German Study Group of Hematology and Oncology (OSHO)

Wolfram Pönisch, Paris S. Mitrou, K Merkle et al. · Journal of Cancer Research and Clinical Oncology · 2006 · 192 citations · Full text

Medicine, Hematology, Oncology +13

Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trials

Carla Casulo, Jesse G. Dixon, Jennifer Le‐Rademacher et al. · Blood · 2022 · 163 citations · Full text

Medicine, Oncology, Survival Analysis +12